Authors:
Gilmore, TD
Cormier, C
Jean-Jacques, J
Gapuzan, ME
Citation: Td. Gilmore et al., Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel, ONCOGENE, 20(48), 2001, pp. 7098-7103
Authors:
Barkett, M
Dooher, JE
Lemonnier, L
Simmons, L
Scarpati, JN
Wang, Y
Gilmore, TD
Citation: M. Barkett et al., Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3, BBA-GEN SUB, 1526(1), 2001, pp. 25-36
Citation: Y. Wang et Td. Gilmore, LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains, BBA-MOL CEL, 1538(2-3), 2001, pp. 260-272
Authors:
Li, CM
Pace, EA
Liang, MC
Lobkovsky, E
Gilmore, TD
Porco, JA
Citation: Cm. Li et al., Total synthesis of the NF-kappa B inhibitor (-)-cycloepoxydon: Utilizationof tartrate-mediated nucleophilic epoxidation, J AM CHEM S, 123(45), 2001, pp. 11308-11309
Authors:
Epinat, JC
Kazandjian, D
Harkness, DD
Petros, S
Dave, J
White, DW
Gilmore, TD
Citation: Jc. Epinat et al., Mutant envelope residues confer a transactivation function onto N-terminalsequences of the v-Rel oncoprotein, ONCOGENE, 19(5), 2000, pp. 599-607
Citation: Jc. Epinat et al., Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells, ONCOGENE, 19(28), 2000, pp. 3131-3137
Citation: Jc. Epinat et Td. Gilmore, Diverse agents act at multiple levels to inhibit the Rel/NF-kappa B signaltransduction pathway, ONCOGENE, 18(49), 1999, pp. 6896-6909